Piboserod
Alternative Names: 207266; SB 207266; SB 207266ALatest Information Update: 20 Apr 2011
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; Serodus
- Class Heart failure therapies; Indoles; Oxazines; Small molecules
- Mechanism of Action Serotonin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
- Discontinued Atrial fibrillation; Irritable bowel syndrome
Most Recent Events
- 18 Jun 2008 Efficacy and adverse events data from a phase II trial in Heart failure released by Bio-Medisinsk Innovasjon
- 31 Jul 2007 Bio-Medisinsk Innovasjon completes a phase II trial in heart failure in Denmark, Norway, and the UK
- 02 Nov 2005 Phase-II clinical trials in Heart failure in United Kingdom (PO)